Skip to content

AVAH Aveanna Healthcare Holdings Inc

NASDAQ
Health Care
Health Care

$12.39

▼ 2.0%

Updated Oct 16, 2:25 PM ET

Report Card

AVAH at a glance — five pillars scored 0–100 from real filed financials.

How the 0–100 rating is calculated
Value
—
Growth
—
Profitability
52
Health
23
Dividends
—

Overall: not rated yet. This stock's fundamentals ratios aren't loaded, so only the pillars its filings support are scored.

Key Metrics

Market Cap

—

P/E

—

Forward P/E (est.)

—

ROE

—

Revenue Growth

—

EPS Growth

—

Profit Margin

—

FCF Yield

—

Debt / Equity

—

ROIC

13.0%

Interest Coverage

1.83x

Current Ratio

1.16x

Dividend Yield

—

Implied Growth (rev. DCF)

—

Rating Score

Not rated

Business Overview

Research

Aveanna Healthcare Holdings Inc (AVAH) is a NASDAQ-listed company in the Health Care industry, within the Health Care sector.

In its latest reported year it generated about $2.43B in revenue and $225.03M in net profit.

Our model hasn't rated AVAH yet because its fundamentals ratios (P/E, margins, returns on capital, leverage) aren't loaded. Any financial history below comes straight from its SEC filings and refreshes automatically.

Economic Moat

Evidence of durable competitive advantage in the filed financials (6 years of history).

Profit margins and economic moats, explained
Narrow moat signalsMoat evidence score: 61/100

Some durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.

Gross margin level30/100

32.0% average over the last 3 years

Gross margin stability87/100

±1.0 pts around 31.3% across 6 years

Revenue durability100/100

grew in 5 of the last 5 year-over-year periods

Free-cash-flow consistency33/100

positive in 4 of 6 years

Return on invested capital40/100

13.0% latest fiscal year

A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.

Revenue Growth

Research
How to read an income statement

4Y CAGR

12.9%

Revenue moved from $1.38B in 2019 to $2.43B in 2026, a 11.9% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.

1/1 checks passedROIC above 10%

Gross Margin

33.3%

Operating Margin

10.5%

Net Margin

9.2%

ROE

—

Debt Analysis

Research
1/2 checks passedInterest covered 3×+Short-term bills covered

Total Debt

$1.30B

Net Debt

$1.20B

Net Debt / EBITDA

4.68x

Debt / Equity

—

Leverage: debt-to-equity is n/a, and operating profit covers interest about 1.8x, with a current ratio of 1.2x. Detailed balance-sheet leverage is limited for this name. It carries roughly $1.30B of total debt against $97.20M of cash.

Cash Flow Analysis

Research

Operating CF

$125.86M

Free Cash Flow

$125.86M

FCF Margin

5.2%

In the latest year Aveanna Healthcare Holdings Inc produced about $125.86M of operating cash flow and $125.86M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.

Valuation Analysis

Research
What is a reasonable P/E ratio?

P/E

—

P/S

—

P/B

—

EV / EBITDA

—

AVAH trades at n/a trailing earnings. Its valuation ratios aren't loaded yet, so there is no P/E to judge here.

Metrics vs. Sector Range

Where AVAH sits versus the Health Care companies we cover.

TTM P/E
——
Forward P/E
——
P/S ratio
——
Revenue growth
——
EPS growth
——
Gross margin
33.3%Weak
Net margin
——
ROE
——

Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in our coverage that have fundamentals data — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.

Sector Peer Comparison

How AVAH stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.

AVAH doesn't have a model rating yet (its fundamentals ratios aren't loaded), so it isn't ranked against the 83 rated Health Care companies we cover.

P/E vs sector

—

median 26.1x

ROE vs sector

—

median 14.1%

Growth vs sector

—

median 7.6%

Sector rank

—

not rated yet

CompanyP/ERev Gr.Rating
AVAHThis stock——Not rated
EHC17.3x10.1%Favorable· 65
GMED18.5x23.5%Strong· 77
FMS11.6x-0.7%Neutral· 53
MOH62.7x7.7%Weak· 28
SNN20.3x6.1%Neutral· 56
PEN73.3x17.3%Neutral· 52
THC10.3x6.6%Favorable· 60
Health Care median26.1x7.6%52/100

Valuation vs. quality map

sector medianEHCGMEDFMSMOHSNNPENTHCP/E — cheaper ←→ pricierROE — more profitable ↑

The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.

Compare side by side

Peers are the closest Health Care companies by sub-industry and size, preferring ones with full data. Sector medians and rank use the 83 rated companies among the 324 Health Care stocks we cover. Educational, not a recommendation.

5-Year Projection Model

Project revenue → earnings → price. Edit the assumptions to build your own case.

What drives this projection, and its limits

2030 scenario price range (Base Case)

$17.69 – $29.49

vs. $12.39 today · implied CAGR 7% – 19%

Metric20262027202820292030
Revenue$2.63B$2.84B$3.07B$3.31B$3.58B
Net income$236.51M$255.43M$275.86M$297.93M$321.77M
EPS$1.08$1.17$1.26$1.37$1.47
Share price (low)$13.01$14.05$15.17$16.38$17.69
Share price (high)$21.68$23.41$25.28$27.31$29.49
CAGR (low–high)5% / 75%6% / 37%7% / 27%7% / 22%7% / 19%

Educational scenario model, not a forecast or investment advice. It starts from the latest annual revenue in SEC filings. By default, growth is trailing revenue growth (held between 3% and 45% a year), the net margin is the latest one (held between 3% and 50%, so a loss-making company is modeled with a small profit), and the Base case P/E runs from 60% to 100% of today's. Carrying recent growth forward five years can miss badly in either direction. Outputs are only as good as the assumptions. Growth, margin or P/E data is missing for this stock, so some starting values above are placeholders rather than measurements.

Key Risks

Research

Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.

Analyst Ratings

What 17 Wall Street analysts covering AVAH recommend (September 2026). Consensus is a useful sanity check — not a substitute for your own homework.

Buy
consensus · score 4.1 / 5 across 17 analysts
Strong Buy 6Buy 7Hold 4Sell 0Strong Sell 0

Analysts have turned more positive over the last three months (+6 pts of buy ratings).

Latest SEC Filings

AVAH's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen. How to read a 10-K

AVAH — frequently asked questions

Is AVAH a good stock to buy?

We don't give buy or sell advice. Review Aveanna Healthcare Holdings Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.

Where does AVAH's data come from?

Live price data plus the annual financials in Aveanna Healthcare Holdings Inc's SEC filings, refreshed automatically. Its fundamentals ratios aren't loaded yet, which is why it has no model rating.

How is the 5-year projection for AVAH calculated?

It's a scenario model. It starts from the latest annual revenue and net margin in SEC filings, grows revenue at an assumed rate (trailing revenue growth by default), and applies a P/E range built around today's multiple to show the resulting share-price range. When a stock has no growth or P/E data, the starting values are placeholders. It's a tool for thinking, not a prediction.

Is this AVAH analysis financial advice?

No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell AVAH. Always do your own research and consider a licensed professional.

Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.

Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.